Satralizumab is a Monoclonal Antibody owned by Chugai Pharmaceutical, and is involved in 14 clinical trials, of which 5 were completed, 7 are ongoing, and 2 are planned.
Satralizumab (Enspryng, SA-237) is a humanized anti-IL-6 receptor antibody that inhibits the cytokine and reduces pro-inflammatory activity. IL-6 involved in signaling pathways that increase inflammatory response. The therapeutic candidate binds to the soluble and membrane bound IL-6 receptors and prevents IL-6 mediated signaling from activating a number of cells involved in immunological and inflammatory response. IL-6 deficiency delays the onset and reduces the severity of collagen-induced arthritis, while blocking the IL-6 receptor leads to diminished joint disease. Thus, Enspryng could be effective for the treatment of autoimmune disorders.
The revenue for Satralizumab is expected to reach a total of $11bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Satralizumab NPV Report.
Satralizumab is originated and owned by Chugai Pharmaceutical. F. Hoffmann-La Roche is the other company associated in development or marketing of Satralizumab.
Satralizumab (Enspryng) is a humanized monoclonal antibody. It is formulated as solution for subcutaneous route of administration. Enspryng is indicated for the treatment of adult and children's with neuromyelitis optica spectrum disorder (NMOSD) and uveitic macular edema. Enspryng is also indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescents patients who are anti-aquaporin-4 (AQP4) antibody positive.
Satralizumab (SA-237) is under development for the treatment of neuromyelitis optica (NMO), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) autoimmune encephalitis and NMO spectrum disorder. It is administered subcutaneously as a solution. SA-237 is a humanized anti IL-6 receptor monoclonal antibody. It is a new molecular entity (NME). The drug candidate is developed from recycling antibody technology. It was also under development for the treatment of rheumatoid arthritis.
It is also under development for the treatment of myasthenia gravis.
F. Hoffmann-La Roche Overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.
Quick View – Satralizumab
|Highest Development Stage|